Thomas Patrick Kelly Sells 1,473 Shares of Deciphera Pharmaceuticals Inc (DCPH) Stock

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) CFO Thomas Patrick Kelly sold 1,473 shares of Deciphera Pharmaceuticals stock in a transaction dated Wednesday, May 22nd. The stock was sold at an average price of $25.06, for a total value of $36,913.38. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Thomas Patrick Kelly also recently made the following trade(s):

  • On Wednesday, May 1st, Thomas Patrick Kelly sold 13,500 shares of Deciphera Pharmaceuticals stock. The stock was sold at an average price of $22.93, for a total value of $309,555.00.

Shares of NASDAQ:DCPH traded up $0.18 during midday trading on Friday, reaching $23.66. 5,306 shares of the company were exchanged, compared to its average volume of 182,885. Deciphera Pharmaceuticals Inc has a one year low of $18.55 and a one year high of $45.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 9.55 and a current ratio of 9.55. The firm has a market cap of $957.78 million, a price-to-earnings ratio of -8.39 and a beta of 3.04.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its earnings results on Thursday, May 9th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.41). As a group, research analysts predict that Deciphera Pharmaceuticals Inc will post -4.32 earnings per share for the current year.

Several institutional investors have recently modified their holdings of DCPH. Rhumbline Advisers boosted its stake in Deciphera Pharmaceuticals by 53.6% during the 4th quarter. Rhumbline Advisers now owns 11,466 shares of the company’s stock valued at $241,000 after purchasing an additional 4,000 shares during the period. Eversept Partners LP acquired a new position in Deciphera Pharmaceuticals in the fourth quarter valued at about $1,463,000. Dimensional Fund Advisors LP acquired a new position in Deciphera Pharmaceuticals in the fourth quarter valued at about $4,337,000. Vanguard Group Inc lifted its position in Deciphera Pharmaceuticals by 2.1% in the third quarter. Vanguard Group Inc now owns 675,517 shares of the company’s stock valued at $26,156,000 after buying an additional 14,081 shares during the last quarter. Finally, MetLife Investment Advisors LLC acquired a new position in Deciphera Pharmaceuticals in the third quarter valued at about $235,000. 56.47% of the stock is currently owned by hedge funds and other institutional investors.

DCPH has been the subject of a number of recent research reports. ValuEngine upgraded Deciphera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 1st. Canaccord Genuity lowered their price target on shares of Deciphera Pharmaceuticals from $55.00 to $50.00 and set a “buy” rating for the company in a report on Friday, March 15th. Zacks Investment Research downgraded Deciphera Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, February 12th. Finally, BidaskClub raised shares of Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, February 2nd. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the company’s stock. Deciphera Pharmaceuticals presently has an average rating of “Hold” and an average price target of $42.11.

WARNING: This news story was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.thestockobserver.com/2019/05/24/thomas-patrick-kelly-sells-1473-shares-of-deciphera-pharmaceuticals-inc-dcph-stock.html.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

See Also: Catch-Up Contributions

Insider Buying and Selling by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.